Provided By GlobeNewswire
Last update: Oct 8, 2024
KANSAS CITY, Kan., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Shane J. Schaffer, Chairman and CEO of Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, recently joined the cast of the Big Biz Show, a business and finance broadcast, to discuss Cingulate’s lead Phase 3 asset CTx-1301 for the treatment of ADHD, its plans for commercialization, and other therapeutic areas where the company’s PTR™ technology may be applied.
NASDAQ:CINGW (11/17/2025, 11:34:17 AM)
0.0321
+0 (+2.88%)
NASDAQ:CING (11/17/2025, 1:24:03 PM)
3.27
-0.22 (-6.3%)
Find more stocks in the Stock Screener


